$KPTI News
Last published 1mo ago
- 1mo agoKPTIKaryopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
- 2mo agoKPTIKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
- 2mo agoKPTIKaryopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with MyelofibrosisPR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has ...
- 3mo agoKPTIKaryopharm Therapeutics 2Q26 Earnings Call - KARYOPHARM THERAPEUTICS INCEarnings Call TranscriptsGood morning. My name is Anas, and I'll be your conference operator today. At this time, I would like to welcome everyone to CarioFarm's SharePredicts 2nd Quarter 2026 Financial Results Conference Call. There will be a q
- 3mo agoKPTIKaryopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA SubmissionPR Newswire– Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis under the Accelerated Approval Pathway Remains on Track – – Planned sNDA for Selinexor plus Ruxolitinib Supported by Phase
- 3mo agoKPTIKaryopharm to Report Second Quarter 2026 Financial Results on August 13, 2026PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will...
- 3mo agoKPTIKaryopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
- 3mo agoKPTIKaryopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval PathwayPR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it...
- 3mo agoKPTIKaryopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial CancerPR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced topline...
- 4mo agoKPTIKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
- 5mo agoKPTIJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORKKARYOPHARM THERAPEUTICS INCEarnings Call TranscriptsHi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome the KaryoPharm team today. We've got Richard Paulson, the CEO, and Reshma Rangwala, the CMO. And it's an exci
- 5mo agoKPTIKaryopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it...
- 5mo agoKPTIKaryopharm Conference Call and WebcastKARYOPHARM THERAPEUTICS INCEarnings Call TranscriptsGood morning. My name is Joelle, and I will be your conference operator today. At this time, I would like to welcome everyone to the CarioFarm Therapeutic Conference Call to discuss today's Phase 3 Sentry Presentation at
- 5mo agoKPTIKaryopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its...
- 5mo agoKPTIKaryopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical OncologyPR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, will present the results of ...
- 5mo agoKPTIKaryopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
- 5mo agoKPTIKaryopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO PresentationPR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it...
- 5mo agoKPTIKaryopharm to Participate at the 2026 Jefferies Global Healthcare ConferencePR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
- 6mo agoKPTIKaryopharm Therapeutics 1Q26 Earnings CallKARYOPHARM THERAPEUTICS INCEarnings Call TranscriptsGood morning, everybody. My name is Kelsey, and I will be your conference operator for today. At this time, I would like to welcome everyone to the CarioFarm Therapeutics First Quarter 2026 Financial Results Conference C
- 6mo agoKPTIKaryopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial EnrollmentPR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial...
- 6mo agoKPTIKaryopharm to Participate at Upcoming Investor ConferencesPR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
- 6mo agoKPTIKaryopharm to Report First Quarter 2026 Financial Results on May 14, 2026PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will...
- 6mo agoKPTIKaryopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual MeetingPR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its...
- 7mo agoKPTIKaryopharm Therapeutics Phase 3 SENTRY Topline Results Conference CallKARYOPHARM THERAPEUTICS INCEarnings Call TranscriptsGood morning. My name is Jenny, and I will be your conference operator today. At this time, I would like to welcome everyone to the Care Reform Therapeutics Call to discuss top-line results from the Phase 3 Sentry Trial.
- 7mo agoKPTIKaryopharm Announces $30 Million Private Placement with RA CapitalPR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has ...
- 7mo agoKPTIKaryopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume ReductionPR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported topline...
- 8mo agoKPTIKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
- 8mo agoACRVERASINCYKPTI+1Registration Momentum Builds Across the Oncology PipelineGlobeNewswireVANCOUVER, British Columbia, Feb. 17, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The FDA's accelerated approval framework continues to deliver measurable population health gains, with a January
- 9mo agoKPTIKaryopharm Therapeutics 4Q25 Earnings CallKARYOPHARM THERAPEUTICS INCEarnings Call TranscriptsGood morning. My name is Ludi, and I will be your conference operator today. At this time, I would like to welcome everyone to the CurioFarm Therapeutics Fourth Quarter and Full Year 2025 Financial Results Conference Cal
- 9mo agoKPTIKaryopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company ProgressPR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial...
- 9mo agoKPTIKaryopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will...
- 9mo agoKPTIKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
- 10mo agoKPTIKaryopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary ...
- 10mo agoKPTIKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
- 11mo agoKPTIKaryopharm to Participate in Baird's Biotech Discovery SeriesPR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
- 11mo agoKPTIKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
- 11mo agoKPTIKaryopharm to Participate at the Piper Sandler 37th Annual Healthcare ConferencePR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
- 1y agoKPTIKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
- 1y agoKPTIKaryopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company ProgressPR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial...
- 1y agoKPTIKaryopharm to Report Third Quarter 2025 Financial Results on November 3, 2025PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will...
- 1y agoKPTIKaryopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in MyelofibrosisPR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has ...
- 1y agoKPTIKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
- 1y agoKPTIApproval of Xpovio, Nda #212306 (Labeling)FDA Approved DrugsApproval Date: 09/26/2025; Drug Name: Xpovio, Nda #212306; Active Ingredients: SELINEXOR; Company: Karyopharm Theraps; Submission Status: Approval; Submission Classification: Labeling; Application Number: 212306
- 1y agoKPTIKaryopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in MyelofibrosisPR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has ...
- 1y agoKPTIKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
- 1y agoKPTIKaryopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoKPTIKaryopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company ProgressPR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial...
- 1y agoKPTIKaryopharm to Report Second Quarter 2025 Financial Results on August 11, 2025PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will...
- 1y agoKPTIKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
- 1y agoKPTIKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...